title: Cancer dormancy: isolation and characterization of dormant lymphoma cells.
abstract: "Tumor dormancy" is an operational term used to describe a prolonged quiescent state in which tumor cells are present, but tumor progression is not clinically apparent. Although clinical examples of tumor dormancy abound, little is known regarding the mechanisms underlying this state. Here we utilize an antibody-induced dormancy model of an aggressive murine B-cell lymphoma (BCL1) and show that the induction of the dormant state is accompanied by dramatic changes in tumor cell morphology and cell cycle status. These data indicate the feasibility of altering the malignant phenotype of transformed cells by specific signals originating at the cell surface, and they suggest new opportunities for therapeutic intervention in cancer.
authors.affiliation: Lautenberg Center of Immunology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
authors.forename: E
authors.initials: E
authors.lastname: Yefenof
authors.forename: L J
authors.initials: LJ
authors.lastname: Picker
authors.forename: R H
authors.initials: RH
authors.lastname: Scheuermann
authors.forename: T F
authors.initials: TF
authors.lastname: Tucker
authors.forename: E S
authors.initials: ES
authors.lastname: Vitetta
authors.forename: J W
authors.initials: JW
authors.lastname: Uhr
mesh_terms: D000818:Animals; D002453:Cell Cycle; D002469:Cell Separation; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000473:pathology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D013154:Spleen / Q000473:pathology; D013997:Time Factors
chemical_list: D000949:Histocompatibility Antigens Class II; D007146:Immunoglobulin lambda-Chains